Good
Mostly Aligned
Patient Risk:
Moderate
Summary
The evaluation correctly identifies the supplied-label support for LYRICA's name, fibromyalgia indication, qualified neuropathic-pain indications, partial-onset seizure use, and mechanism, and appropriately classifies exercise-specific claims as unsupported. However, it introduces several safety and population assertions based on label sections that were not supplied and makes an unsupported statement that fatigue or asthenia may appear in adverse-reaction tables.
Category Scores
Accurate Statements
The label identifies the product as LYRICA (pregabalin).
Section 11 describes LYRICA as pregabalin.
Fibromyalgia is an indicated use.
Section 1 lists management of fibromyalgia.
The epilepsy claim is only partially supported because the label specifies adjunctive therapy for partial-onset seizures.
Section 1 specifies adjunctive treatment of partial-onset seizures in patients 1 month of age and older.
The broad neuropathic-pain claim requires qualification.
Section 1 limits the listed neuropathic-pain indications to diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury.
The mechanism claim is a simplified but generally supported description.
Section 12.1 describes alpha2-delta binding and effects on neurotransmitter release and pain transmission.
The exercise-specific claims are not supported by the supplied label sections.
The supplied sections do not discuss exercise capacity, workout intensity, workout type, or exercise safety.
Dizziness and somnolence are labeled adverse reactions and occur more frequently at higher doses.
Section 5.5 states that LYRICA may cause dizziness and somnolence and that both occur more frequently at higher doses.
Unsupported Statements
Fatigue or asthenia may appear among adverse reactions depending on the indication and table.
The supplied label excerpts do not provide adverse-reaction tables or support this statement.
Respiratory depression, suicidal behavior and ideation, angioedema, hypersensitivity, abrupt-discontinuation risks, renal dosing, pregnancy, lactation, and pediatric limitations are important omissions from the audited claims.
The cited sections and their contents were not supplied, so these assertions cannot be evaluated or established using the provided prescribing information.
The current LYRICA prescribing information does not appear to contain a boxed warning.
No boxed-warning section or complete prescribing information was supplied.
The cited discontinuation warning section numbering should be verified against the specific label revision.
This is an external qualification about label revisions, not information supported by the supplied label sections.
Contradictions
Important Omissions
The evaluation could have explicitly noted that the supplied excerpts do not include the complete dosage-and-administration section or the other warning, interaction, and specific-population sections used in its proposed omissions.
Importance:
Moderate
The indication assessment could have listed the exact labeled indications, including postherpetic neuralgia and neuropathic pain associated with spinal cord injury, rather than only describing the broad neuropathic-pain claim as qualified.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The evaluation does not directly give treatment advice and correctly rejects unsupported exercise claims. However, it presents multiple safety and population assertions as label-based omissions even though the cited sections were not included in the supplied prescribing information, which could mislead readers about what was verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
The response extends its audit beyond the supplied label excerpts and treats several unavailable sections as verified support for additional safety and population omissions.
Suggested Improvement
Limit conclusions to the supplied sections. State that the additional warnings, renal dosing, discontinuation, pregnancy, lactation, pediatric, interaction, and boxed-warning content cannot be evaluated because those sections were not provided.